Tecentriq (Atezolizumab) is an immune checkpoint inhibitor used in conjunction with chemotherapy or other cancer medications to attack cancer cells. By blocking PD-L1, a protein on some cancer cells, Tecentriq allows the immune system to recognize and target cancer cells. Clinical trials show that Tecentriq extends survival and improves outcomes in patients with lung cancer, bladder cancer, and triple-negative breast cancer. Tecentriq is generally well-tolerated, administered intravenously once every three or four weeks, and monitored for potential side effects. Tecentriq is FDA-approved for several types of cancer, making it a promising treatment option for many cancer patients.